Identification of novel genes involved in apoptosis of HIV-infected macrophages using unbiased genome-wide screening.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
07 Jul 2021
Historique:
received: 15 11 2020
accepted: 15 06 2021
entrez: 8 7 2021
pubmed: 9 7 2021
medline: 13 7 2021
Statut: epublish

Résumé

Macrophages, besides resting latently infected CD4+ T cells, constitute the predominant stable, major non-T cell HIV reservoirs. Therefore, it is essential to eliminate both latently infected CD4+ T cells and tissue macrophages to completely eradicate HIV in patients. Until now, most of the research focus is directed towards eliminating latently infected CD4+ T cells. However, few approaches have been directed at killing of HIV-infected macrophages either in vitro or in vivo. HIV infection dysregulates the expression of many host genes essential for the survival of infected cells. We postulated that exploiting this alteration may yield novel targets for the selective killing of infected macrophages. We applied a pooled shRNA-based genome-wide approach by employing a lentivirus-based library of shRNAs to screen novel gene targets whose inhibition should selectively induce apoptosis in HIV-infected macrophages. Primary human MDMs were infected with HIV-eGFP and HIV-HSA viruses. Infected MDMs were transfected with siRNAs specific for the promising genes followed by analysis of apoptosis by flow cytometry using labelled Annexin-V in HIV-infected, HIV-exposed but uninfected bystander MDMs and uninfected MDMs. The results were analyzed using student's t-test from at least four independent experiments. We validated 28 top hits in two independent HIV infection models. This culminated in the identification of four target genes, Cox7a2, Znf484, Cstf2t, and Cdk2, whose loss-of-function induced apoptosis preferentially in HIV-infected macrophages. Silencing these single genes killed significantly higher number of HIV-HSA-infected MDMs compared to the HIV-HSA-exposed, uninfected bystander macrophages, indicating the specificity in the killing of HIV-infected macrophages. The mechanism governing Cox7a2-mediated apoptosis of HIV-infected macrophages revealed that targeting respiratory chain complex II and IV genes also selectively induced apoptosis of HIV-infected macrophages possibly through enhanced ROS production. We have identified above-mentioned novel genes and specifically the respiratory chain complex II and IV genes whose silencing may cause selective elimination of HIV-infected macrophages and eventually the HIV-macrophage reservoirs. The results highlight the potential of the identified genes as targets for eliminating HIV-infected macrophages in physiological environment as part of an HIV cure strategy.

Sections du résumé

BACKGROUND BACKGROUND
Macrophages, besides resting latently infected CD4+ T cells, constitute the predominant stable, major non-T cell HIV reservoirs. Therefore, it is essential to eliminate both latently infected CD4+ T cells and tissue macrophages to completely eradicate HIV in patients. Until now, most of the research focus is directed towards eliminating latently infected CD4+ T cells. However, few approaches have been directed at killing of HIV-infected macrophages either in vitro or in vivo. HIV infection dysregulates the expression of many host genes essential for the survival of infected cells. We postulated that exploiting this alteration may yield novel targets for the selective killing of infected macrophages.
METHODS METHODS
We applied a pooled shRNA-based genome-wide approach by employing a lentivirus-based library of shRNAs to screen novel gene targets whose inhibition should selectively induce apoptosis in HIV-infected macrophages. Primary human MDMs were infected with HIV-eGFP and HIV-HSA viruses. Infected MDMs were transfected with siRNAs specific for the promising genes followed by analysis of apoptosis by flow cytometry using labelled Annexin-V in HIV-infected, HIV-exposed but uninfected bystander MDMs and uninfected MDMs. The results were analyzed using student's t-test from at least four independent experiments.
RESULTS RESULTS
We validated 28 top hits in two independent HIV infection models. This culminated in the identification of four target genes, Cox7a2, Znf484, Cstf2t, and Cdk2, whose loss-of-function induced apoptosis preferentially in HIV-infected macrophages. Silencing these single genes killed significantly higher number of HIV-HSA-infected MDMs compared to the HIV-HSA-exposed, uninfected bystander macrophages, indicating the specificity in the killing of HIV-infected macrophages. The mechanism governing Cox7a2-mediated apoptosis of HIV-infected macrophages revealed that targeting respiratory chain complex II and IV genes also selectively induced apoptosis of HIV-infected macrophages possibly through enhanced ROS production.
CONCLUSIONS CONCLUSIONS
We have identified above-mentioned novel genes and specifically the respiratory chain complex II and IV genes whose silencing may cause selective elimination of HIV-infected macrophages and eventually the HIV-macrophage reservoirs. The results highlight the potential of the identified genes as targets for eliminating HIV-infected macrophages in physiological environment as part of an HIV cure strategy.

Identifiants

pubmed: 34233649
doi: 10.1186/s12879-021-06346-7
pii: 10.1186/s12879-021-06346-7
pmc: PMC8261936
doi:

Substances chimiques

RNA, Small Interfering 0
enhanced green fluorescent protein 0
Green Fluorescent Proteins 147336-22-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

655

Références

Cancer Treat Rev. 2009 May;35(3):280-8
pubmed: 19117685
Science. 1999 Nov 12;286(5443):1353-7
pubmed: 10558989
FEBS Lett. 1994 Feb 14;339(1-2):40-4
pubmed: 8313978
PLoS One. 2012;7(5):e35297
pubmed: 22567100
Hum Mol Genet. 2007 May 15;16(10):1241-52
pubmed: 17403714
Asian Pac J Allergy Immunol. 2001 Jun;19(2):139-44
pubmed: 11699721
Front Microbiol. 2019 Dec 05;10:2828
pubmed: 31866988
Retrovirology. 2012 Oct 04;9:82
pubmed: 23035819
Curr Opin Infect Dis. 2013 Dec;26(6):561-6
pubmed: 24152764
Melanoma Res. 2019 Apr;29(2):126-133
pubmed: 30451788
Nat Med. 2002 Apr;8(4):319-23
pubmed: 11927927
Sci Rep. 2017 Oct 9;7(1):12866
pubmed: 28993666
Virology. 2009 Oct 10;393(1):160-7
pubmed: 19692106
J Biol Chem. 2004 Aug 20;279(34):36059-71
pubmed: 15218037
Protein Cell. 2016 Dec;7(12):854-865
pubmed: 27743346
J Leukoc Biol. 2003 Nov;74(5):650-6
pubmed: 12960230
Genesis. 2008 Sep;46(9):447-62
pubmed: 18781633
J Virol. 2016 Jun 24;90(14):6255-6262
pubmed: 27122585
Biochim Biophys Acta. 2014 Apr;1837(4):418-26
pubmed: 24183696
JCI Insight. 2016 Dec 8;1(20):e88255
pubmed: 27942584
Trends Microbiol. 2016 May;24(5):345-355
pubmed: 26875617
AIDS. 2012 Jun 19;26(10):1261-8
pubmed: 22472858
Viral Immunol. 2016 Nov;29(9):532-533
pubmed: 27564791
J Virol. 2007 Nov;81(22):12596-607
pubmed: 17728233
Cancer Res. 2009 Mar 1;69(5):1782-91
pubmed: 19223549
Viruses. 2012 Nov 09;4(11):3020-43
pubmed: 23202514
Oxid Med Cell Longev. 2016;2016:8910396
pubmed: 27829986
Clin Cancer Res. 2011 Sep 15;17(18):5889-900
pubmed: 21813631
Curr HIV Res. 2008 Sep;6(5):388-400
pubmed: 18855649
EMBO J. 2003 Jun 2;22(11):2821-30
pubmed: 12773396
Antiviral Res. 2002 Aug;55(2):209-25
pubmed: 12103427
Methods. 2011 Jan;53(1):20-6
pubmed: 20627127
Genome Res. 2007 May;17(5):566-76
pubmed: 17387143
Genome Res. 2014 Mar;24(3):377-89
pubmed: 24249727
Clin Sci (Lond). 2016 Mar;130(6):393-407
pubmed: 26846578
Curr Opin Infect Dis. 2014 Feb;27(1):29-35
pubmed: 24296585
Aging (Albany NY). 2016 May;8(5):889-98
pubmed: 27070172
Mol Cancer. 2009 Jun 23;8:39
pubmed: 19549337
Pathog Immun. 2017;2(2):179-192
pubmed: 28752134
J Immunol. 2011 Dec 1;187(11):5865-78
pubmed: 22068233
Immunol Rev. 2013 Jul;254(1):54-64
pubmed: 23772614
Chem Res Toxicol. 2008 Nov;21(11):2073-81
pubmed: 18956847
J Histochem Cytochem. 1979 Jan;27(1):36-43
pubmed: 220325
Cell Prolif. 2003 Jun;36(3):131-49
pubmed: 12814430
Tissue Eng Part C Methods. 2012 Mar;18(3):198-204
pubmed: 21981657
Oxid Med Cell Longev. 2015;2015:217670
pubmed: 26294939
J Proteomics. 2012 Aug 3;75(15):4693-704
pubmed: 22365974
Sci Rep. 2018 Dec 7;8(1):17732
pubmed: 30531981
J Immunol. 2001 Feb 1;166(3):1863-70
pubmed: 11160233
RNA Biol. 2020 Jun;17(6):755-764
pubmed: 32050839
J Infect Dis. 2012 Jun 15;205(12):1778-87
pubmed: 22476717
Cell Host Microbe. 2015 Sep 9;18(3):345-53
pubmed: 26355217
Retrovirology. 2019 Feb 7;16(1):3
pubmed: 30732620
Hum Mol Genet. 2014 Nov 15;23(22):5866-78
pubmed: 24939910
J Virol. 2016 Aug 12;90(17):7596-606
pubmed: 27307568
Oncotarget. 2016 Aug 2;7(31):50027-50042
pubmed: 27418135
Viruses. 2014 Apr 22;6(4):1837-60
pubmed: 24759213
J Virol. 2013 Apr;87(8):4716-27
pubmed: 23408629
FEBS J. 2017 Jan;284(1):97-113
pubmed: 27981746
Retrovirology. 2015 Nov 17;12:97
pubmed: 26577226
Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2270-4
pubmed: 11854523
Mitochondrion. 2004 Jul;4(2-3):235-54
pubmed: 16120389
Hum Gene Ther. 1996 Aug 20;7(13):1527-34
pubmed: 8864753
Trends Cancer. 2019 Jan;5(1):11-29
pubmed: 30616753
Apoptosis. 2000 Nov;5(5):415-8
pubmed: 11256882
J Virol. 2017 Jan 31;91(4):
pubmed: 27928019
J Virol. 1999 Jun;73(6):4561-6
pubmed: 10233914
PLoS Pathog. 2012;8(8):e1002861
pubmed: 22876188
J Innate Immun. 2010;2(3):204-15
pubmed: 20375558
Curr Opin Struct Biol. 2001 Feb;11(1):39-46
pubmed: 11179890
Mol Syst Biol. 2013 Oct 08;9:696
pubmed: 24104479
Cold Spring Harb Protoc. 2016 Jul 01;2016(7):
pubmed: 27371595
Antivir Chem Chemother. 2009 Oct 19;20(2):63-78
pubmed: 19843977
J Cell Mol Med. 2017 Feb;21(2):402-409
pubmed: 27758070
Mitochondrion. 2007 Jul;7(4):284-7
pubmed: 17395552
Semin Cell Dev Biol. 2015 Mar;39:132-8
pubmed: 25550219
J Virol. 1997 Apr;71(4):3219-27
pubmed: 9060685
Antiviral Res. 2010 Jan;85(1):286-94
pubmed: 19808057
PLoS One. 2013 Jul 29;8(7):e69450
pubmed: 23922713
Mol Cell Ther. 2014 Apr 02;2:10
pubmed: 26056579
Retrovirology. 2004 Jun 23;1:12
pubmed: 15214962
Curr HIV Res. 2004 Jan;2(1):51-9
pubmed: 15053340
Cell Host Microbe. 2018 Jan 10;23(1):14-26
pubmed: 29324227
Cell Death Dis. 2020 Jul 27;11(7):590
pubmed: 32719312
Mol Syst Biol. 2014 Jul 01;10:733
pubmed: 24987113
Eur J Clin Invest. 2000 May;30(5):454-9
pubmed: 10809906

Auteurs

Simon X M Dong (SXM)

Apoptosis Research Center, Children's Hospital of Eastern Ontario, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Department of Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Frederick S Vizeacoumar (FS)

Department of Pathology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.

Kalpana K Bhanumathy (KK)

Department of Pathology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.

Nezeka Alli (N)

Department of Pathology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.

Cristina Gonzalez-Lopez (C)

Cancer Research, Saskatchewan Cancer Agency, 107 Wiggins Road, Saskatoon, SK, Canada.

Niranjala Gajanayaka (N)

Apoptosis Research Center, Children's Hospital of Eastern Ontario, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Ramon Caballero (R)

Apoptosis Research Center, Children's Hospital of Eastern Ontario, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Department of Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Hamza Ali (H)

Apoptosis Research Center, Children's Hospital of Eastern Ontario, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Department of Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Andrew Freywald (A)

Department of Pathology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.

Edana Cassol (E)

Department of Health Sciences, Carleton University, Ottawa, ON, Canada.

Jonathan B Angel (JB)

Department of Medicine, the Ottawa Health Research Institute, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Franco J Vizeacoumar (FJ)

Department of Pathology, College of Medicine, University of Saskatchewan, Saskatoon, SK, Canada. franco.vizeacoumar@usask.ca.
Cancer Research, Saskatchewan Cancer Agency, 107 Wiggins Road, Saskatoon, SK, Canada. franco.vizeacoumar@usask.ca.

Ashok Kumar (A)

Apoptosis Research Center, Children's Hospital of Eastern Ontario, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. akumar@uottawa.ca.
Department of Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. akumar@uottawa.ca.
Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. akumar@uottawa.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH